Physician profile
Jared Lander
NPI 1215390877
$5,068.08
in general payments reported to CMS, 2019-2025
27 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $219 · 2021: $409 · 2022: $766 · 2023: $608 · 2024: $1,516 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,565.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.31 | 2020-2025 | |
| Gilead Sciences, INC. | $646.40 | 2021-2025 | Epclusa, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $491.52 | 2022-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $366.30 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $278.43 | 2020-2025 | Omvoh |
| Ardelyx, INC. | $264.35 | 2023-2025 | Ibsrela |
| Pfizer INC. | $245.36 | 2019-2025 | |
| Janssen Biotech, INC. | $183.37 | 2023-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $154.25 | 2024-2025 | |
| Qol Medical, LLC | $124.50 | 2024-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $120.67 | 2023-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $118.65 | 2023-2024 | Suflave, Sutab |
| Celltrion USA INC. | $112.70 | 2024-2025 | Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $105.63 | 2019-2022 | |
| Medtronic, INC. | $85.37 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $65.89 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $60.14 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $55.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $47.77 | 2019-2024 | Zeposia |
| Novo Nordisk INC | $35.62 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.73 | 2019 | |
| Exact Sciences Corporation | $18.80 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $18.43 | 2020 | |
| Ferring Pharmaceuticals INC. | $18.03 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $16.25 | 2024 | Dificid |
| Amag Pharmaceuticals, INC. | $15.79 | 2019 | |
| Redhill Biopharma INC. | $14.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Lander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.